Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology, Inc. (Nasdaq: CRDF) is a clinical-stage biotechnology company dedicated to developing novel cancer therapies. Leveraging their proprietary PLK1 inhibition technology, Cardiff Oncology focuses on creating innovative treatments for various cancers with significant unmet medical needs.
Cardiff Oncology's lead therapeutic asset is onvansertib, a highly selective Polo-like kinase 1 (PLK1) inhibitor. This investigational drug is currently being evaluated in clinical trials for its effectiveness in treating multiple types of cancer, including RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC).
Recent achievements include promising clinical data for onvansertib monotherapy and combination therapy in mPDAC and SCLC trials. The mPDAC Phase 2 trial reported a 19% objective response rate (ORR) and a median progression-free survival (mPFS) of 5.0 months, compared to historical controls with an ORR of 7.7% and mPFS of 3.1 months. In SCLC, onvansertib monotherapy has demonstrated encouraging single-agent activity.
Cardiff Oncology continues to expand its clinical programs and research partnerships. They announced a first-line trial in mPDAC in collaboration with Oregon Health & Science University (OHSU) Knight Cancer Institute, exploring both monotherapy and combination therapy with standard care. Furthermore, the company highlights an ongoing Phase 1b/2 study for KRAS-mutated mCRC, which has shown a favorable safety profile and promising efficacy results.
Financially, Cardiff Oncology reported a strong cash position with approximately $81.4 million in cash, cash equivalents, and short-term investments as of September 30, 2023. Their operational strategy is supported by partnerships and ongoing research endeavors, which are projected to fund operations into 2025.
The company's forward-looking initiatives include the advancement of their lead program in RAS-mutated mCRC to the first-line setting and continuous exploration of onvansertib's potential in various cancer treatments. Investors and stakeholders can stay updated through regular business updates and conference calls hosted by Cardiff Oncology.
Cardiff Oncology, a clinical-stage biotechnology company, announced that CEO Mark Erlander will present at the 2022 Virtual Growth Conference from March 28-30, 2022. The fireside chat is scheduled for March 28 at 2:30 PM ET. The conference will be hosted by Maxim Group LLC and streamed live on M-Vest. Additionally, Dr. Erlander will provide a pre-recorded overview of the company's clinical and corporate strategy. Cardiff Oncology focuses on developing therapies targeting cancers using its lead asset, onvansertib, a PLK1 inhibitor. For more information, visit their website.
Cardiff Oncology (Nasdaq: CRDF) announced the acceptance of two abstracts for poster presentations at the AACR Annual Meeting from April 8-13, 2022 in New Orleans. The presentations focus on their lead asset, onvansertib, a promising PLK1 inhibitor. The first abstract discusses biomarkers for mCRPC patients receiving onvansertib with abiraterone, while the second highlights combination therapy's potential against PARP inhibitor resistance. These findings aim to advance treatment options for cancer patients.
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology firm, will join Cowen's 42nd Annual Healthcare Conference for a panel discussion and investor meetings from March 7-9, 2022. The panel, focusing on Gastrointestinal/Genitourinary Oncology, is scheduled for March 8, 2022, at 10:30 AM ET. Cardiff is advancing its lead drug, onvansertib, a third-generation PLK1 inhibitor, aimed at treating various cancers including KRAS-mutated colorectal cancer. A replay of the panel will be accessible on Cardiff's website for 30 days post-conference.
Cardiff Oncology (Nasdaq: CRDF) reported significant progress in its KRAS-mutated metastatic colorectal cancer (mCRC) program, with patient numbers increasing from 14 to 48. Initial data showed a robust objective response rate of 35% and a median progression-free survival (mPFS) of 9.4 months. A $15 million equity investment from Pfizer at a premium of 19% per share further supports the company's growth. Total operating expenses for Q4 2021 increased to $9.6 million, largely due to ongoing clinical programs. The company ended 2021 with approximately $141 million in cash.
On January 31, 2022, Cardiff Oncology (Nasdaq: CRDF) announced the granting of stock options to a new employee, totaling 55,008 shares. The options, priced at $3.38 per share, reflect the stock's closing price on the grant date. These inducements are in compliance with Nasdaq Listing Rule 5635(c)(4) and will vest over four years, contingent on the employee's continued employment. Cardiff Oncology focuses on innovative cancer treatments, including its investigational drug, onvansertib, targeting KRAS-mutated cancers and other high-need indications.
Cardiff Oncology, a clinical-stage oncology company targeting unmet medical needs in cancer treatment, announced its participation in the B. Riley Securities 2022 Oncology Conference, scheduled for January 27-28, 2022. The company will present on January 28, 2022, at 2:00 PM ET. Their lead investigational drug, onvansertib, is a first-in-class Polo-like Kinase 1 (PLK1) inhibitor, currently evaluated in three clinical programs focused on KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer. A replay of the presentation will be available post-conference.
Cardiff Oncology (Nasdaq: CRDF) has released new data regarding its lead clinical trial of onvansertib combined with FOLFIRI/bevacizumab for treating KRAS-mutated metastatic colorectal cancer (mCRC). The Phase 1b/2 trial shows significant efficacy with 34% initial complete or partial responses among patients at the recommended dose and 94% achieving disease control. Notably, the median progression-free survival is reported at 9.4 months, exceeding historical controls. Results will be highlighted at the ASCOGI symposium on January 22, 2022.
Cardiff Oncology (Nasdaq: CRDF) has appointed Tod Smeal, Ph.D., as chief scientific officer and Charles Monahan, RPh, as senior vice president of regulatory affairs, as it advances its treatment pipeline. Smeal brings over 20 years of experience in targeted therapies, crucial for the development of onvansertib, a first-in-class Polo-like Kinase 1 inhibitor aimed at difficult-to-treat cancers. Monahan's regulatory expertise will facilitate the drug's journey towards approval. The company is focused on unmet needs in KRAS-mutated colorectal cancer and other severe cancers, aiming for improved patient outcomes.
Cardiff Oncology, Inc. (Nasdaq: CRDF) announced a conference call and webcast on January 18, 2022, at 5:00 PM ET, to discuss updated data from its lead clinical program in KRAS-mutated metastatic colorectal cancer. The data will also be featured at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI), happening from January 20-22, 2022 in San Francisco. Cardiff is developing onvansertib, a first-in-class Polo-like Kinase 1 inhibitor, to improve cancer treatment outcomes in various indications.
Cardiff Oncology (Nasdaq: CRDF) announced its participation at the H.C. Wainwright BioConnect Virtual Conference from January 10 to 13, 2022. The presentation will be available on-demand starting at 7:00 AM ET on January 10. Cardiff Oncology focuses on developing precision medicine for cancer patients, specifically targeting KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer. Their investigational drug, onvansertib, is a third-generation Polo-like Kinase 1 inhibitor designed to improve treatment responses and overall survival.
FAQ
What is the current stock price of Cardiff Oncology (CRDF)?
What is the market cap of Cardiff Oncology (CRDF)?
What is Cardiff Oncology's primary focus?
What is onvansertib?
Which cancers is Cardiff Oncology targeting with onvansertib?
What are the recent clinical achievements of Cardiff Oncology?
What is the financial condition of Cardiff Oncology?
What are the upcoming milestones for Cardiff Oncology?
How can investors stay updated about Cardiff Oncology?
What partnerships does Cardiff Oncology have?
What is the significance of PLK1 in cancer treatment?
Where can more information about Cardiff Oncology be found?
